Top ranking for Ambulatory RCM Services, Government Reimbursement Services, and Underpayment Recovery Services underscores domain expertise and technology capabilities
MURRAY, Utah, February 7, 2024 – R1 RCM Inc. (NASDAQ: RCM) (“R1”), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced that it was ranked number one in three Best in KLAS categories for 2024, including a fourth consecutive award in the Ambulatory RCM Services (EHR-Agnostic) category. Now an 11-time Best in KLAS winner, R1 also earned top rankings this year for Government Reimbursement Services and Underpayment Recovery Services, the first and third time winning in these categories, respectively.
“We appreciate the trust our clients place in us to navigate a challenging environment for providers, and this recognition by KLAS underscores our dedication to helping providers achieve optimal financial and operating performance,” said Lee Rivas, CEO of R1 RCM. “Healthcare providers need us now more than ever, and we are committed to meeting them where they are and helping them on their journey. The Best in KLAS awards validate our team’s efforts to understand our clients’ needs and partner with them to deliver measurable and sustainable results.”
Clients awarded R1 high marks for bringing advanced automation, deep expertise, and operational performance that helped them realize strong financial results and enhanced patient experiences. R1’s ability to integrate across multiple EHR's, maximize earned reimbursement for Medicare cost reports, and recover missed revenue opportunities make R1 a trusted partner in delivering comprehensive solutions that providers seek.
As healthcare providers confront shrinking margins resulting from reimbursement and cost pressures, and workforce shortages, R1 is helping physician groups improve their financial performance by optimizing workflows that remove the in-house administrative burdens linked to coding, billing, and AR follow-up.
R1 clients surveyed by KLAS expressed their satisfaction with the company’s Ambulatory RCM Services, with one hospital CEO commenting in October 2023, “R1 is evolving in a challenging and changing healthcare business environment. They are bringing a resource to bear.”
With ongoing regulatory and contractual complexity, healthcare providers are struggling to optimize revenue. Merging automation and artificial intelligence with deep healthcare regulatory expertise, R1’s underpayment recovery and government reimbursement services are helping clients address the root causes of these issues through staff education and operational improvement.
According to one hospital executive in December 2023, “We brought the firm on board and immediately saw increased revenue. R1 was able to point out where we were missing money, and once we figured out what we were missing, we were able to change our practices. We can get ahead of things now in ways we couldn't before. If we don't agree with what the firm recommends, they are open to discussions because we involve our coders as well. We like that R1 listens to us.”
“R1 is an excellent partner,” noted another hospital executive in November 2023. “I would call them a partner, not a vendor. They have been with us for a long time, and as technology grows, they grow with it.”
Based entirely on provider and payer feedback, the Best in KLAS designation is awarded to the software and services solutions that have the broadest operational and clinical impact on healthcare organizations. For more information about R1’s award-winning suite of revenue cycle solutions, visit r1rcm.com.
R1 is a leading provider of technology-driven solutions that transform the patient experience and financial performance of hospitals, health systems and medical groups. R1’s proven and scalable operating models seamlessly complement a healthcare organization’s infrastructure, quickly driving sustainable improvements to net patient revenue and cash flows while reducing operating costs and enhancing the patient experience. To learn more, visit: r1rcm.com.
KLAS is a research and insights firm on a global mission to improve healthcare. Working with thousands of healthcare professionals and clinicians, KLAS gathers data and insights on software and services to deliver timely reports and performance data that represent provider and payer voices and act as catalysts for improving vendor performance. The KLAS research team publishes reports covering the most pressing questions facing healthcare technology today, including emerging technology insights, that provide early insights on the future of healthcare technology solutions. KLAS also fosters measurement and collaboration between healthcare providers and payers and best practice adoption. Learn more at klasresearch.com.
This press release contains “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements generally relate to future events and relationships, plans, future growth and future performance. These statements are often identified by the use of words such as “anticipate,” “believe,” “contemplate,” “designed,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “outlook,” “plan,” “predict,” “project,” “see,” “seek,” “should,” “target,” “would” and similar expressions or variations or negatives of these words, although not all forward-looking statements contain these identifying words. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of R1’s management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, assurance, prediction or definitive statement of fact or probability. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks and changes in circumstances, including but not limited to risks and uncertainties related to R1’s ability to timely and successfully achieve the anticipated benefits and potential synergies of the acquisition of Acclara and related transactions and the impact of the restatements of the financial statements for non-reliance periods on the price of R1’s common stock, reputation and relationships with investors, suppliers, customers, employees and other parties. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included under the heading “Risk Factors” in R1’s Amendment No. 1 to Annual Report on Form 10-K/A for the year ended December 31, 2022, quarterly reports on Form 10-Q and any other periodic reports that R1 may file with the Securities and Exchange Commission. The foregoing list of factors is not exhaustive. All forward-looking statements included herein are expressly qualified in their entirety by these cautionary statements as of the date hereof and involve many risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements. Subsequent events and developments, including actual results or changes in R1’s assumptions, may cause R1’s views to change. R1 assumes no obligation and does not intend to update these forward-looking statements, except as required by law. You are cautioned not to place undue reliance on such forward-looking statements.
# # #
Evan Smith, CFA
Content written on behalf of R1 RCM.